TNS 9.55.3

**TNS 9.55.3** is a clinical-grade lentiviral vector developed by Errant Gene Therapeutics (EGT) under an exclusive license from Sloan Kettering Institute for use in gene therapy targeting beta-thalassemia. It is designed for ex vivo transduction of patient hematopoietic stem cells to correct the underlying genetic defect in beta-globin production, potentially offering a curative approach by enabling functional beta-globin expression and reducing dependence on lifelong blood transfusions and chelation therapy. The vector received orphan drug designation from the FDA and EMEA, with protocol approval from the NIH Recombinant DNA Advisory Committee in 2007; clinical trials were planned to commence in late 2011 at Memorial Sloan Kettering Cancer Center.[3][5][13]